This review discusses the landmark studies in the field of multiple myeloma (MM) 
which were presented at American society of hematology annual meeting, 2016. 
There were contrary results from two large phase III trials (one from US and one 
from Europe) that evaluated the role of additional interventions like tandem 
autologous transplant (ASCT) and consolidation after induction therapy followed 
by ASCT in newly diagnosed MM (NDMM) patients, but there were critical 
differences between the two studies. Novel agents like carfilzomib and ixazomib 
proved to be of benefit when used as induction and post ASCT consolidation and 
maintenance in NDMM. The early data on subcutaneous administration of 
daratumumab (DARA) looked promising. The high rate of minimal residual disease 
negativity after using DARA even in relapsed/refractory MM (RRMM) setting 
reinforces the benefit of targeting CD38. The responses seen with venetoclax in 
RRMM with t(11;14)(high BCL-2, low BCL-XL and MCL-1) and selinexor in 
penta-refractory myeloma which fulfills the FDA category of unmet need, opens up 
newer options for these patients. BCMA CAR-T infusion shows encouraging results 
in advanced refractory myeloma patients.